000			01828cam a2200301zu 4500
001			88815011
003			FRCYB88815011
005			20250107211708.0
006			m o d
007			cr un
008			250107s2008 fr | o|||||0|0|||eng d
020			_a9782742007134
035			_aFRCYB88815011
040			_aFR-PaCSA _ben _c _erda
100	1		_aKahane, Philippe
245	0	1	_aDrug-Resistant Epilepsies _c['Kahane, Philippe', 'Berg, Anne', 'Löscher, Wolfgang']
264		1	_bJohn Libbey Eurotext _c2008
300			_a p.
336			_btxt _2rdacontent
337			_bc _2rdamdedia
338			_bc _2rdacarrier
650		0	_a
700	0		_aKahane, Philippe
700	0		_aBerg, Anne
700	0		_aLöscher, Wolfgang
856	4	0	_2Cyberlibris _uhttps://international.scholarvox.com/netsen/book/88815011 _qtext/html _a
520			_aMore than 12 million people with epilepsy have seizures that cannot be controlled by antiepileptic drugs. The term "drug-resistance" is abundantly used in the epilepsy literature but the definitions proposed differ considerably. It is used indifferently in a number of different settings: as a criterion for selection of patients eligible for new antiepileptic drug trials, for the selection of surgical candidates, for the design of epidemiological studies, for the design of studies on quality of life, for the definition of the epileptic encephalopathies (in comparison to more benign epilepsy syndromes), to mention but a few. As a result, available studies are usually not comparable and referral to epilepsy specialists is unacceptably delayed. The present volume of Progress in Epileptic Disorders includes several focused chapters on all issues relating to drug-resistance and offers the basis for a consensus on a clinically meaningful core definition.
999			_c61764 _d61764